USP CLASS VI CERTIFICATION

The complexities of medical device bio-compatibility can be difficult to navigate. In this post, we will explain how plastics are classified and tested to ensure patient safety.

The U.S. Pharmacopeial Convention (USP) is a nonprofit organization responsible for creating standards for a variety of healthcare elements, including devices and equipment. The USP promotes bio-compatibility for plastics and polymers that come in contact with patient tissue. For these materials, there are six classes, with VI being the most stringent. While the first five classifications are valuable for certain materials, Class VI is the most compatible for medical applications.

USP Class VI – Three Evaluations to Ensure Safety

For the USP Class VI, there are three tests that materials must meet to be deemed safe. There are four standards that these evaluations test: purity, strength, quality and consistency. Here are the three tests explained:

  • Acute Systemic Toxicity measures the toxicity and irritation when a sample of the material is administered orally, placed on the skin or inhaled. It is extracted in up to four solutions: saline, vegetable oil, alcohol saline and polyethylene glycol. The test model is then observed for three days to determine any ill effects.
  • Intracutaneous determines the material’s toxicity and localized irritation when it touches live skin. It is extracted using the same four solutions. Test and control sites are compared to see if there is any significant reaction.
  • Implantation assesses toxicity, infection and irritation of intramuscular These implantations are observed for five to seven days to determine if there is any negative response.

These tests focus on toxicity while evaluating temperature over specific time periods. If a material does meet rigorous USP Class VI standards, then it is likely to be accepted by the FDA and USDA. Class VI testing encompasses any kind of possible applications that include the standard polar and nonpolar extracts required for ISO 10993-12 for completed devices. It’s considered the gold standard for medical-grade raw materials.

The USP Class testing was initially intended for polymers but can also be used to test other materials that encounter patients. The Class labels are meant to represent real-world usage.

EVA from Presco Meets Class VI

EVA (ethylene-vinyl acetate), is a copolymer consisting of ethylene and vinyl acetate. This medical grade film is a soft, clear material that can be RF-welded to create medical solution containers and tubing sets.

With rising concerns regarding the use of PVC in medical applications, EVA has been found to be a suitable alternative for medical use. In fact, for medical bags, EVA is the preferred choice—it has proven track record spanning three decades of wide use in medical device applications, particularly in IV therapy.

Why Choose EVA?

  • 30% lighter than PVC for a better yield and lower shipping costs
  • EVA has better tear and burst strength
  • Exceptional sealing properties
  • Strong impact resistance and cold crack properties
  • Meets all regulatory requirements of the market
  • Bio-compatible as certified with USP Class VI testing
  • No plasticizers or chlorine
  • Printable for fill lines

Pres-Flex EVA is Presco’s first PVC-free manufacturing capability for engineered film. To learn more about USP Class VI certified EVA film from Presco, contact us today. Our team of experienced professionals can guide you through your organization’s unique needs to determine whether this highly-favored PVC alternative is appropriate for your manufacturing processes.

Follow us on social media for the latest updates in B2B!

Image

Latest

skilled trades mentorship
Why the Modern Data Center Is Forcing Communities and Policymakers to Rethink Infrastructure
April 21, 2026

Data centers have moved from largely invisible digital infrastructure to a highly visible source of public debate as artificial intelligence accelerates demand for power, fiber, and compute capacity. The modern data center is now being built closer to population centers to support low-latency services, bringing critical infrastructure into direct contact with residential communities for…

Read More
Inside the Spot Freight Shift: How Manifold Is Simplifying a Fragmented Logistics Market
April 21, 2026

The freight market is in the midst of a notable shift. With national tender rejection rates approaching 14% by the end of Q1, freight conditions have shifted back in carriers’ favor, often coinciding with increased activity in the spot market. At the same time, logistics teams are juggling an increasingly fragmented ecosystem of portals, emails,…

Read More
healthcare 2026
Healthcare’s 2026 Reality: Growing Workforce Gaps, Tiered Access, and the Rise of AI Support
April 20, 2026

Healthcare systems are entering 2026 under mounting pressure. A growing, aging population and rising disease burden are colliding with persistent workforce shortages—highlighted by projections that new cancer diagnoses in the U.S. will surpass two million this year alone. The stakes are no longer theoretical: delays in care, limited specialist access, and widening disparities are…

Read More
Mental Health Care
Policy, AI, and New Funding Models Are Reshaping Mental Health Care Delivery
April 16, 2026

Mental health care isn’t a new problem—but it’s finally being treated like an urgent one. After years of being sidelined, the cracks in the system are becoming impossible to ignore: overstretched clinicians, long wait times, and entire communities without consistent access to care. In the U.S., the scale is striking—more than one in five…

Read More